IDH1 and epilepsy: Our study showed that the IDH1 positive mutation incidence in glioma patients with epilepsy was 23.4%, which was different from IDH1 negative mutation incidence in the NO BTRE group (13.9%), and the difference was statistically significant, which suggested that IDH1 positive mutation was closely related to BTRE in glioma patients.